FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396702906> ?p ?o ?g. }

• W2396702906 abstract "Immune therapies have had limited success in the treatment of metastatic cancers despite the accumulation of intra-tumoral antigen-specific T cells. The tumor microenvironment (TME) is partly responsible for these failures through active blockade of local antitumor immune responses and facilitation of immune escape. Extracellular proteinases, such as metalloproteinases (MMPs), are key components in promoting tumor progression through modulation of the TME. MMP-2 (gelatinase A or collagenase IV) cleaves many components of the extracellular matrix and its active form is over-expressed in several cancers including melanoma as compared to normal tissue. High MMP-2 levels in cancer and/or stromal cells are often associated with later tumor stages, increased dissemination and poorer survival/prognosis. The main purpose of this study is to characterize the mechanisms underlying the influence of MMP-2, derived from tumor stroma or malignant cells, on the tumor infiltrating immune cells so as to develop effective cancer therapies. Our lab has previously demonstrated that upon antigenic stimulation, MMP-2-specific CD4+ T cells derived from patients with metastatic melanoma secrete inflammatory TH2 cytokines, i.e. TNFα, IL-4 and IL-13 but no or little IFNγ and IL-2. We subsequently showed that active MMP-2 drives the differentiation of TH2 responses by inhibiting IL-12p70 production and up-regulating OX40L expression on dendritic cells (DCs). OX40L is a key co-stimulatory molecule for the priming of TH2 cells, especially in the absence of IL-12. Recently, we published our novel discovery identifying both enzymatically active and inactive MMP-2 as ligands for TLR2 on DCs, and showed that MMP-2 mediated TLR2 stimulation lead to up-regulation OX40L on DCs (Cell Reports, 2014). Here we aim to identify a novel link between MMP-2-TLR-2 cross talk in human melanoma progression and survival both in vitro and in vivo. We have screened several human melanoma cell lines for expression of Toll Like Receptors (TLRs) and responsiveness to TLR ligands. Moreover these cell lines have been tested for expression and secretion of pro-MMP-2 and active MMP-2 using techniques such as RT-PCR, Western blotting, flowcytometry ELISA, zymography and CBA analysis. Over all, specific cell lines have been identified that express high levels of both MMP-2 and TLR2 or express none/low levels of MMP-2 and TLR2. These cell lines will be used for performing in vitro tumor invasion assays in the presence and absence of TLR2 neutralizing antibodies to determine relative importance of autocrine MMP-2-TLR2 signaling for melanoma invasiveness. Thereafter CRISPR/Cas9 technology will be utilized for stably knocking down MMP-2, TLR2 or both in select lines and tested for invasiveness in vitro. Finally, these cells lines will be transferred into immuno-compromised NOD/SCID/IL-2gR-/- mice to determine if presence or absence of melanoma derived MMP-2 and/or TLR2 signaling could physiologically alter tumor progression. Our previous research and current data indicate that MMP-2 acts simultaneously as an endogenous TH2 “conditioner” and tumor-associated antigen. Therefore delving into both enzymatic and non-enzymatic MMP-2 signaling mechanisms in the TME holds a strong potential for discovering novel therapeutic options for treating melanoma. Furthermore, results from this study stand to provide crucial information that will expand our global understanding of tumorigenesis. Citation Format: Mansi Saxena, Luciana R. Muniz, Nina Bhardwaj. Matrix metalloproteinase-2 modulates inflammation and melanoma progression via TLR2. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B160." @default.
• W2396702906 created "2016-06-24" @default.
• W2396702906 creator A5009433941 @default.
• W2396702906 creator A5055358847 @default.
• W2396702906 creator A5090472768 @default.
• W2396702906 date "2016-01-01" @default.
• W2396702906 modified "2023-10-09" @default.
• W2396702906 title "Abstract B160: Matrix metalloproteinase-2 modulates inflammation and melanoma progression via TLR2" @default.
• W2396702906 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b160" @default.
• W2396702906 hasPublicationYear "2016" @default.
• W2396702906 type Work @default.
• W2396702906 sameAs 2396702906 @default.
• W2396702906 citedByCount "0" @default.
• W2396702906 crossrefType "proceedings-article" @default.
• W2396702906 hasAuthorship W2396702906A5009433941 @default.
• W2396702906 hasAuthorship W2396702906A5055358847 @default.
• W2396702906 hasAuthorship W2396702906A5090472768 @default.
• W2396702906 hasConcept C109523444 @default.
• W2396702906 hasConcept C121608353 @default.
• W2396702906 hasConcept C126322002 @default.
• W2396702906 hasConcept C16930146 @default.
• W2396702906 hasConcept C189165786 @default.
• W2396702906 hasConcept C203014093 @default.
• W2396702906 hasConcept C2776107976 @default.
• W2396702906 hasConcept C2776914184 @default.
• W2396702906 hasConcept C2777658100 @default.
• W2396702906 hasConcept C2777701055 @default.
• W2396702906 hasConcept C2779256057 @default.
• W2396702906 hasConcept C2780674031 @default.
• W2396702906 hasConcept C502942594 @default.
• W2396702906 hasConcept C71924100 @default.
• W2396702906 hasConcept C86803240 @default.
• W2396702906 hasConcept C8891405 @default.
• W2396702906 hasConcept C95444343 @default.
• W2396702906 hasConceptScore W2396702906C109523444 @default.
• W2396702906 hasConceptScore W2396702906C121608353 @default.
• W2396702906 hasConceptScore W2396702906C126322002 @default.
• W2396702906 hasConceptScore W2396702906C16930146 @default.
• W2396702906 hasConceptScore W2396702906C189165786 @default.
• W2396702906 hasConceptScore W2396702906C203014093 @default.
• W2396702906 hasConceptScore W2396702906C2776107976 @default.
• W2396702906 hasConceptScore W2396702906C2776914184 @default.
• W2396702906 hasConceptScore W2396702906C2777658100 @default.
• W2396702906 hasConceptScore W2396702906C2777701055 @default.
• W2396702906 hasConceptScore W2396702906C2779256057 @default.
• W2396702906 hasConceptScore W2396702906C2780674031 @default.
• W2396702906 hasConceptScore W2396702906C502942594 @default.
• W2396702906 hasConceptScore W2396702906C71924100 @default.
• W2396702906 hasConceptScore W2396702906C86803240 @default.
• W2396702906 hasConceptScore W2396702906C8891405 @default.
• W2396702906 hasConceptScore W2396702906C95444343 @default.
• W2396702906 hasLocation W23967029061 @default.
• W2396702906 hasOpenAccess W2396702906 @default.
• W2396702906 hasPrimaryLocation W23967029061 @default.
• W2396702906 hasRelatedWork W1219680990 @default.
• W2396702906 hasRelatedWork W1840729935 @default.
• W2396702906 hasRelatedWork W1978432266 @default.
• W2396702906 hasRelatedWork W2030882091 @default.
• W2396702906 hasRelatedWork W2059580444 @default.
• W2396702906 hasRelatedWork W2143580209 @default.
• W2396702906 hasRelatedWork W2333777598 @default.
• W2396702906 hasRelatedWork W2548094500 @default.
• W2396702906 hasRelatedWork W2903322254 @default.
• W2396702906 hasRelatedWork W2910570709 @default.
• W2396702906 hasRelatedWork W2954374238 @default.
• W2396702906 hasRelatedWork W2977186857 @default.
• W2396702906 hasRelatedWork W2998829477 @default.
• W2396702906 hasRelatedWork W3016604606 @default.
• W2396702906 hasRelatedWork W3046980718 @default.
• W2396702906 hasRelatedWork W3132499090 @default.
• W2396702906 hasRelatedWork W3158712105 @default.
• W2396702906 hasRelatedWork W3214526595 @default.
• W2396702906 hasRelatedWork W75097064 @default.
• W2396702906 hasRelatedWork W3030958949 @default.
• W2396702906 isParatext "false" @default.
• W2396702906 isRetracted "false" @default.
• W2396702906 magId "2396702906" @default.
• W2396702906 workType "article" @default.